Cidara Therapeutics presents preclinical data on CBO421

Cidara Therapeutics announced new preclinical data on its drug-Fc conjugate candidate, CBO421, at the Society for Immunotherapy of Cancer’s 38th Annual Meeting. The conference is taking place November 1-5, 2023, both virtually and in-person in San Diego, CA. “We look forward to sharing data that demonstrate the potential for CBO421 to potently inhibit tumor growth as both a monotherapy and in combination with PD-1 therapies,” said Jeffrey Stein, Ph.D. president and chief executive officer of Cidara. “CD73 plays a significant role in contributing to immune evasion in solid tumors. CBO421, our CD73-targeting DFC, combines the strengths of small molecule inhibitors and monoclonal antibodies against CD73 and demonstrates the potential for best-in-class activity to fully exploit the CD73 target to inhibit immune evasion by cancer cells in-vivo. Based on these data, we’re excited to advance this candidate into clinical trials for the treatment of solid tumors.”